Zobrazeno 1 - 10
of 2 356
pro vyhledávání: '"Kenneth C. Anderson"'
Autor:
Arghya Ray, Ting Du, Xueping Wan, Yan Song, Sindhu C. Pillai, Md. Abu Musa, Teng Fang, Jared Moore, Brian Blank, Xiaohui Du, Xi Chen, Robert Warne, Dena Sutimantanapi, Fang Lui, Tatiana Zavorotinskaya, Christophe Colas, Lori Friedman, Melissa R. Junttila, Dharminder Chauhan, Kenneth C. Anderson
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-6 (2024)
Highlights CD73 is the key ectoenzyme involved in the generation of AMP-derived adenosine, which contributes to immunosuppression in the MM BM milieu. Blocking CD73 activity with a potent, selective, orally bioavailable CD73 inhibitor ORIC-533 decrea
Externí odkaz:
https://doaj.org/article/cb600363d6c64299b15c0ef4fcde06f7
Autor:
Jiye Liu, Lijie Xing, Jiang Li, Kenneth Wen, Ning Liu, Yuntong Liu, Gongwei Wu, Su Wang, Daisuke Ogiya, Tian-Yu Song, Keiji Kurata, Johany Penailillo, Eugenio Morelli, Tingjian Wang, Xiaoning Hong, Annamaria Gulla, Yu-Tzu Tai, Nikhil Munshi, Paul Richardson, Ruben Carrasco, Teru Hideshima, Kenneth C. Anderson
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood. Here, we identify, via two in vitro genome-wide
Externí odkaz:
https://doaj.org/article/7f2fe4cc076c4f8aab09d7ab7cfd3475
Autor:
Debasmita Dutta, Jiye Liu, Kenneth Wen, Keiji Kurata, Mariateresa Fulciniti, Annamaria Gulla, Teru Hideshima, Kenneth C. Anderson
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Bortezomib (BTZ) is a standard-of-care treatment in multiple myeloma (MM); however, adverse side effects and development of resistance limit its long term benefit. To improve target specificity, therapeutic efficacy, and overcome resistance,
Externí odkaz:
https://doaj.org/article/7d50b6f504af47028426c84f41e90866
Autor:
Paul G. Richardson, Aurore Perrot, Jesus San Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A. Dimopoulos, Shang-Yi Huang, Jiri Minarik, Michele Cavo, H. Miles Prince, Sandrine Macé, Rick Zhang, Franck Dubin, Mony Chenda Morisse, Kenneth C. Anderson
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The primary and pre-specified updated analyses of ICARIA-MM (NCT02990338) demonstrated improved progression-free survival and a benefit in overall survival (OS) was reported with the addition of isatuximab, an anti-CD38 monoclonal antibody, to pomali
Externí odkaz:
https://doaj.org/article/2cdeb822507640969679ff3be53cc866
Autor:
Jian Cui, Tengteng Yu, Rui Lv, Jiahui Liu, Huishou Fan, Wenqiang Yan, Jingyu Xu, Chenxing Du, Shuhui Deng, Weiwei Sui, Matthew Ho, Yan Xu, Kenneth C. Anderson, Xifeng Dong, Lugui Qiu, Gang An
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Deeper depth of response (DpR) after induction therapy, especially gain of negative minimal residual disease (MRD), has been linked to prolonged survival in multiple myeloma (MM). However, flow-MRD examination focuses on the numbers but n
Externí odkaz:
https://doaj.org/article/d2351facc29a43f9a0ab3bba64b55009
Autor:
Daisuke Ogiya, Zuzana Chyra, Sigitas J. Verselis, Morgan O’Keefe, Jacquelyn Cobb, Ivane Abiatari, Srikanth Talluri, Anjana Anilkumar Sithara, Teru Hideshima, Michael P. Chu, Roman Hájek, David M. Dorfman, Linda M. Pilarski, Kenneth C. Anderson, Sophia Adamia
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Novel drug discoveries have shifted the treatment paradigms of most hematological malignancies, including multiple myeloma (MM). However, this plasma cell malignancy remains incurable, and novel therapies are therefore urgently needed. Whole
Externí odkaz:
https://doaj.org/article/0720ebfef4374a3d981cb2d875066c2e
Autor:
Keiji Kurata, Anna-James Bott, Mark A. Tye, Leona Yamamoto, Mehmet K. Samur, Yu-Tzu Tai, James Dunford, Catrine Johansson, Filiz Senbabaoglu, Martin Philpott, Charlotte Palmer, Karthik Ramasamy, Sarah Gooding, Mihaela Smilova, Giorgia Gaeta, Manman Guo, John C. Christianson, N. Connor Payne, Kritika Singh, Kubra Karagoz, Matthew E. Stokes, Maria Ortiz, Patrick Hagner, Anjan Thakurta, Adam Cribbs, Ralph Mazitschek, Teru Hideshima, Kenneth C. Anderson, Udo Oppermann
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress. We here show that glutamyl-prolyl-tRNA synthetase (GluProRS) inhibition c
Externí odkaz:
https://doaj.org/article/9a68487f85794fbbb8d94c8c96041cdb
Autor:
Anil Aktas Samur, Mariateresa Fulciniti, Herve Avet-Loiseau, Michael A. Lopez, Sanika Derebail, Jill Corre, Stephane Minvielle, Florence Magrangeas, Philippe Moreau, Kenneth C. Anderson, Giovanni Parmigiani, Mehmet K. Samur, Nikhil C. Munshi
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 12, Pp 1-11 (2022)
Abstract Splicing changes are common in cancer and are associated with dysregulated splicing factors. Here, we analyzed RNA-seq data from 323 newly diagnosed multiple myeloma (MM) patients and described the alternative splicing (AS) landscape. We obs
Externí odkaz:
https://doaj.org/article/8f433518944f46019120b39f11b9a13b
Autor:
Paul G. Richardson, Brian G. Durie, Laura Rosiñol, Maria-Victoria Mateos, Angela Dispenzieri, Philippe Moreau, Shaji Kumar, Noopur Raje, Nikhil Munshi, Jacob P. Laubach, Peter O’Gorman, Elizabeth O’Donnell, Peter Voorhees, Thierry Facon, Joan Bladé, Sagar Lonial, Aurore Perrot, Kenneth C. Anderson
Publikováno v:
Haematologica, Vol 108, Iss 11 (2023)
To improve the outcomes of patients with the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of r
Externí odkaz:
https://doaj.org/article/ff2c261954ee4ceb9b055acf9843022f
Autor:
Hailin Chen, Tengteng Yu, Liang Lin, Lijie Xing, Shih-Feng Cho, Kenneth Wen, Kimberly Aardalen, Adwait Oka, Joni Lam, Mike Daley, Haihui Lu, Nikhil Munshi, Kenneth C. Anderson, Yu-Tzu Tai
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 8, Pp 1-10 (2022)
Abstract We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multiple myeloma (MM) cell lysis and immunomodulatory effects induced by bispecific antibodies (BisAbs). GSIs-induced membrane BCMA (mBCMA) accum
Externí odkaz:
https://doaj.org/article/18630a073f974d81b53cefcf6ea2de9d